论文部分内容阅读
为了观察奥沙利铂联合表柔比星及5-FU(EOF方案)对多发转移性胃癌的近期疗效及安全性,对病理确诊的36例多发转移性胃癌患者进行化疗。化疗方案:奥沙利铂100mg/m2静脉滴入2h,d1;5-FU500mg/m2持续静脉滴入4h,d1～d5;表柔比星50mg/m2,静脉推注,d1,每2周重复,至少完成2个周期判效。36例可评价疗效及不良反应,治疗总周期数125个周期,平均4.5个周期。CR3例(8.3%),PR16例(44.4%),总缓解率RR52.6%,SD22.2%(8/36),PD25%(9/36),KPS评分提高>20者38.9%(14/36),CBR改善者占50.0%。Ⅲ度/Ⅳ度主要不良反应为中性粒细胞减少19.4%(7/36),血小板减少11.1%(4/36),贫血8.3%(3/36),恶心、呕吐8.3%(3/36),腹泻2.8%(1/36),末梢神经感觉异常11.1%(4/36)。初步研究结果提示,奥沙利铂联合表柔比星和5-FU治疗多发转移性胃癌疗效肯定,不良反应能够耐受。
In order to observe the short-term efficacy and safety of oxaliplatin plus epirubicin and 5-FU (EOF regimen) in the treatment of multiple metastatic gastric cancer, 36 patients with pathologically diagnosed multiple metastatic gastric cancer were treated with chemotherapy. Chemotherapy: oxaliplatin 100mg / m2 intravenous infusion 2h, d1; 5-FU500mg / m2 continuous intravenous infusion 4h, d1 ~ d5; epirubicin 50mg / m2, intravenous injection, d1, repeated every 2 weeks , At least 2 cycles to complete the judgment. Thirty-six cases were evaluated for efficacy and adverse reactions. The total number of cycles was 125 cycles with an average of 4.5 cycles. The overall CR rate was RR 52.6%, SD 22.2% (8/36), PD 25% (9/36), KPS score> 20 38.9% (14 cases), CR 3 (8.3% / 36), CBR improvement accounted for 50.0%. Grade Ⅲ / Ⅳ major adverse reactions were neutropenia 19.4% (7/36), thrombocytopenia 11.1% (4/36), anemia 8.3% (3/36), nausea and vomiting 8.3% (3/36 ), Diarrhea 2.8% (1/36), peripheral nerve sensory abnormalities 11.1% (4/36). Preliminary results suggest that oxaliplatin in combination with epirubicin and 5-FU for the treatment of multiple metastatic gastric cancer positive effect, adverse reactions can tolerate.